Abstract
There have been few prospective studies about the efficacy and safety of antiherpesvirus drugs for Kaposi's varicelliform eruption(KVE). In the present study,we investigated the efficacy(patients analyzed,n=114)and safety(patients analyzed,n=131)of famciclovir(FCV)in FCV-naïve patients with KVE. Assessment of overall improvement and the frequency of side effects during the approximate period from the start of FCV administration to three weeks after completion of administration(Day 21)showed that among patients analyzed for efficacy,the proportion of patients determined to have an overall improvement of “marked improvement” or “improvement”(improvement rate)was 96.5%,and none of the patients were determined to have an “exacerbation”. The median number of days until complete crust formation was seven days,and the median number of days until healing was eight days. In addition,among patients analyzed for safety,the frequency of side effects was 0.8%. These results confirmed the efficacy and safety of FCV in patients with KVE. We also analized the relationships between the hearing time and the severity of KVE, severity or treatment contents of atopic dermatitis, the most common underlying disease of KVE.
